Tian F.S.,Tianjin Gong an Hospital |
Luo R.,Tianjin Gong an Hospital |
Zhao Z.Q.,Tianjin Gong an Hospital |
Wu Y.,Tianjin Gong an Hospital |
Ban D.J.,Tianjin Gong an Hospital
Experimental and Clinical Endocrinology and Diabetes | Year: 2010
Aims: This observational study aimed to investigate the effects of renin-angiotensin system (RAS) blockers on plasma adiponectin in subjects with metabolic syndrome (Mets) and differentiation, adiponectin expression of human omental (OM) and subcutaneous (SC) preadipocytes. Methods: Fifty-three patients with Mets were treated with angiotensin converting enzyme inhibition (ACEI), angiotensin II receptor blocker (ARB) or nothing, lipid profile and adiponetin were measured. OM and SC preadipocytes were obtained from sixteen normal non-menopausal women undergoing elective abdominal surgery and subsequently differentiated in the presence of ACE, ARB or thiazolidinedione (TZD). Differentiation was assessed using a number of biochemical and function parameters. Results: Plasma adiponectin was increased dramatically as a result of ACEI and ARB treatment. Most of the metabolic and differentiating parameters were improved significantly by RAS blockers or TZD. Compared with TZD, RAS blockers have stronger effects on omental preadipocytes in differentiation and insulin sensitivity. The improvement of adiponectin mRNA expression was significantly greater in ARB-treated omental preadipocytes compared with TZD-treated ones. Conclusion: These results suggest that adiponectin may serve as potential therapeutic targets of ACEI and ARB for treating the Mets and its related complications. It also suggests a potential benefit of RAS blockers on Mets with characteristic visceral obesity. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart - New York.
Zhao Z.-Q.,Tianjin Medical University |
Luo R.,Tianjin Gong an Hospital |
Li L.-Y.,Tianjin Medical University |
Tian F.-S.,Tianjin Gong an Hospital |
And 3 more authors.
Canadian Journal of Diabetes | Year: 2013
Objectives: This study aims to investigate the effects of telmisartan, pioglitazone and metformin administration on the prevention of new-onset type 2 diabetes mellitus in pre-diabetes Otsuka Long-Evans Tokushima Fatty (OLETF) rats fed with a high-fat diet (HFD). Methods: OLETF rats 22 weeks of age were treated with pioglitazone (O-P), metformin (O-M), telmisartan (O-T) and low telmisartan starting from their pre-diabetes period. The weight, glucose tolerance and insulin sensitivity were measured. The lipid profiles were obtained. The abdominal subcutaneous (SC) and omental (OM) fat pads were dissected to measure the expression of mRNA and protein levels (adiponectin, proinflammatory cytokines, etc.). Results: Telmisartan significantly reversed glucose tolerance and improved insulin resistance. The incidence rates of impaired glucose tolerance and type 2 diabetes in the O-P (χ2 = 11.025, p=0.001) and O-T (χ2=5.495, p=0.019) groups were significantly reduced. The mRNA expression of proinflammatory cytokines was downregulated by telmisartan. The expression of adiponectin, PPARγ1 and γ2 was markedly improved by telmisartan and pioglitazone compared with the OLETF control (O-C) group. The correlation analysis showed that the systolic and diastolic blood pressures were not correlated with the homeostasis model assessment-insulin resistance (p>0.05). Conclusions: Telmisartan acts beneficially against diabetes-induced inflammation and improves insulin resistance in pre-diabetes OLETF rats fed with HFD. In view of this improved responsiveness to insulin sensitivity, telmisartan may prove to be a promising candidate for the intervention treatment of the pre-diabetes state. © 2013 Canadian Diabetes Association.